Amgen today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced pancreatic cancer who received LUMAKRAS® (sotorasib). The data will be presented at the monthly American Society of Clinical Oncology (ASCO) Plenary Series on Feb. 15, 2022. Data show encouraging and clinically meaningful…

eTurboNews izindatshana ezababhalisi kuphela. Ukubhalisa kuyinto MAHHALA.
Ababhalisile bangena lapha Chofoza lapha ukuze ubhalise MAHHALA

LOKHO ONGAKUTHATHE KULESI SIHLOKO:

The data will be presented at the monthly American Society of Clinical Oncology (ASCO) Plenary Series on Feb.
Amgen today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced pancreatic cancer who received LUMAKRAS® (sotorasib).
Data show encouraging and clinically meaningful….